Wells Fargo analyst Mohit Bansal raised the firm’s price target on Eli Lilly to $650 from $615 and keeps an Overweight rating on the shares. The firm’s analysis of obesity-related comorbidities and its new model makes it see $50B-plus obesity opportunity, 90% weighted toward co-morbidities. This raises Wells’ conviction into Eli Lilly becoming the first trillion dollar Bio-pharma.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Eli Lilly (NYSE:LLY) Jumps on Analyst Optimism
- Point Biopharma downgraded to Market Perform from Outperform at Leerink
- Eli Lilly price target raised to $700 from $600 at BofA
- Jefferies healthcare analysts to hold an analyst/industry conference call
- Maxim starts Acrivon Therapeutics at Buy, sees ACR-368 as ‘just the beginning’